From induced-proximity approaches to emerging strategies for overcoming drug resistance, advancing cancer therapeutics requires deeper insights into target engagement, molecular mechanisms, and therapeutic selectivity.
ICE Bioscience will be attending the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) from November 18-20 in Barcelona, Spain, where we'll present three scientific posters featuring our latest advances on transformative platforms and approaches in oncology discovery:
✅ ER-BRD4 RIPTAC: Bridging Target Engagement to a Target-Dependent Therapeutic Window
✅ AR–BRD4 RIPTAC Induces Expression-Dependent Ternary Complex Formation to Achieve Tumor-Selective Target Engagement in Prostate Cancer
✅ Characterization and Overcoming of KRAS-Targeted Therapy Resistance in Resistant Cancer Cell Lines
Join us at Booth #6 and dive into our featured posters. Let's discuss how our integrated platform can accelerate your pipeline.
Location: Barcelona, Spain
Date: November 18-20, 2026
Booth: #6
PREV：Join Our Expert Oral Presentation at the...
NEXT：There's no more
2026-10-23
2026-10-21
2026-10-16
2026-10-16
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
